Skip to main content

Main menu

  • Home
  • Current Issue
  • Content
    • Current Issue
    • Early Access
    • Multimedia
    • Podcast
    • Collections
    • Past Issues
    • Articles by Subject
    • Articles by Type
    • Supplements
    • Plain Language Summaries
    • Calls for Papers
  • Info for
    • Authors
    • Reviewers
    • Job Seekers
    • Media
  • About
    • Annals of Family Medicine
    • Editorial Staff & Boards
    • Sponsoring Organizations
    • Copyrights & Permissions
    • Announcements
  • Engage
    • Engage
    • e-Letters (Comments)
    • Subscribe
    • Podcast
    • E-mail Alerts
    • Journal Club
    • RSS
    • Annals Forum (Archive)
  • Contact
    • Contact Us
  • Careers

User menu

  • My alerts

Search

  • Advanced search
Annals of Family Medicine
  • My alerts
Annals of Family Medicine

Advanced Search

  • Home
  • Current Issue
  • Content
    • Current Issue
    • Early Access
    • Multimedia
    • Podcast
    • Collections
    • Past Issues
    • Articles by Subject
    • Articles by Type
    • Supplements
    • Plain Language Summaries
    • Calls for Papers
  • Info for
    • Authors
    • Reviewers
    • Job Seekers
    • Media
  • About
    • Annals of Family Medicine
    • Editorial Staff & Boards
    • Sponsoring Organizations
    • Copyrights & Permissions
    • Announcements
  • Engage
    • Engage
    • e-Letters (Comments)
    • Subscribe
    • Podcast
    • E-mail Alerts
    • Journal Club
    • RSS
    • Annals Forum (Archive)
  • Contact
    • Contact Us
  • Careers
  • Follow annalsfm on Twitter
  • Visit annalsfm on Facebook
Research ArticleOriginal ResearchA

Cardiovascular Risk and Statin Use in the United States

Michael Edward Johansen, Lee A. Green, Ananda Sen, Sheetal Kircher and Caroline R. Richardson
The Annals of Family Medicine May 2014, 12 (3) 215-223; DOI: https://doi.org/10.1370/afm.1641
Michael Edward Johansen
1Department of Family Medicine, The Ohio State University, Columbus, Ohio
2Department of Family Medicine, University of Michigan, Ann Arbor, Michigan
MD, MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Michael.Johansen@osumc.edu
Lee A. Green
2Department of Family Medicine, University of Michigan, Ann Arbor, Michigan
3Department of Family Medicine, University of Alberta, Alberta, Canada
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ananda Sen
2Department of Family Medicine, University of Michigan, Ann Arbor, Michigan
4Department of Biostatistics, University of Michigan, Ann Arbor, Michigan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheetal Kircher
5Department of Internal Medicine, Hematology Oncology, Northwestern University, Evanston, Illinois
MD, MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline R. Richardson
2Department of Family Medicine, University of Michigan, Ann Arbor, Michigan
6VA Ann Arbor Health Care System, Ann Arbor, Michigan
7VA Center for Clinical Management Research, Ann Arbor, Michigan
MD, MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Probability of statin use by presence of coronary artery disease, according to sex and presence of hyperlipidemia.

    CAD = coronary artery disease.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Probability of statin use by presence of diabetes after age 40, according to sex and presence of hyperlipidemia.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Probability of statin use in an individual without diabetes or coronary artery disease by modified cardiovascular risk index, according to sex.

Tables

  • Figures
  • Additional Files
    • View popup
    Table 1

    Characteristics of Study Sample and Subsamples of Individuals Aged 30 to 79 Years

    CharacteristicOverall SampleCoronary Artery DiseaseDiabetes and Aged >40 Years
    TotalOn StatinNot on StatinTotalOn StatinNot on StatinTotalOn StatinNot on Statin
    Individuals, No.16,7122,79913,9131,3046946082,0169921,019
    Weighted proportion, %–18.8
    (18.0–19.7)
    81.2
    (80.3–82.0)
    –58.2
    (54.6–61.7)
    41.8
    (38.3–45.4)
    –52.0
    (49.4–54.6)
    48.0
    (45.4–50.6)
    Population in millions, No.166
    (159–173)
    31.2
    (29.2–33.2)
    135
    (129–140)
    13.4
    (12.3–14.5)
    7.8
    (7.0–8.6)
    5.6
    (4.9–6.3)
    18.7
    (17.3–20.0)
    9.7
    (8.9–10.6)
    9.0
    (8.2–9.8)
    Age, y51.3
    (51.0–51.6)
    61.1
    (60.6–61.6)a
    49.0
    (48.7–49.3)a
    62.9
    (62.3–63.6)
    64.9
    (64.1–65.7)a
    60.2
    (59.1–61.4)a
    60.3
    (59.6–60.9)
    61.8
    (61.1–62.6)a
    58.5
    (57.6–59.4)a
    Sex, female, %50.8
    (50.2–51.4)
    46.7
    (44.8–48.7)b
    51.7
    (50.9–52.5)b
    41.4
    (38.4–44.5)
    37.8
    (33.6–42.3)b
    46.4
    (41.9–51.1)b
    49.3
    (46.8–51.8)
    49.8
    (46.0–53.6)
    48.8
    (44.8–52.8)
    Tobacco users, %18.6
    (17.7–19.5)
    16.4
    (14.8–18.2)b
    19.1
    (18.1–20.1)b
    21.7
    (18.5–25.3)
    19.7
    (15.9–24.0)b
    24.7
    (20.5–29.4)b
    17.0
    (15.1–19.0)
    15.7
    (13.4–18.4)
    18.3
    (15.5–21.5)
    Hypertension, %39.2
    (38.1–40.3)
    70.7
    (68.2–72.7)b
    31.9
    (30.8–33.1)b
    80.3
    (77.6–82.8)
    84.2
    (80.6–87.4)b
    74.8
    (70.7–78.5)b
    81.1
    (78.8–83.1)
    86.0
    (83.1–88.6)b
    75.7
    (72.1–78.9)b
    Hyperlipidemia, %38.4
    (37.5–39.3)
    95.8
    (94.8–96.6)b
    25.1
    (24.3–26.0)b
    78.7
    (76.2–81.1)
    94.3
    (92.0–96.0)b
    57.1
    (52.7–61.4)b
    77.4
    (75.0–79.5)
    94.8
    (92.7–96.3)b
    58.5
    (54.7–62.3)b
    Race/ethnicity, %
     White69.5
    (67.6–71.3)
    77.8
    (76.0–80.3)b
    67.5
    (65.5–69.5)b
    74.9
    (71.8–77.7)
    80.3
    (76.7–83.4)b
    67.3
    (62.1–72.1)b
    62.8
    (59.4–66.1)
    67.3
    (63.3–71.0)b
    58.0
    (53.3–62.5)b
     Black11.2
    (10.1–12.5)
    9.4
    (8.0–11.0)
    11.6
    (10.4–13.0)
    11.5
    (9.6–13.6)
    9.1
    (6.9–12.1)
    14.8
    (11.9–18.2)
    16.4
    (14.0–19.0)
    14.4
    (11.9–17.4)
    18.4
    (15.2–21.5)
     Hispanic12.8
    (11.4–14.3)
    7.2
    (6.1–8.5)
    14.1
    (12.6–15.8)
    8.2
    (6.4–10.5)
    5.4
    (4.0–7.3)
    12.2
    (8.9–16.3)
    13.0
    (11.0–15.3)
    10.2
    (8.1–12.7)
    16.9
    (14.0–22.2)
     Asian4.7
    (3.9–5.6)
    3.6
    (2.6–4.9)
    4.9
    (4.2–5.9)
    2.7
    (1.8–4.0)
    3.2
    (2.1–4.9)
    1.9
    (1.0–3.7)
    4.4
    (3.4–5.7)
    4.9
    (3.5–6.7)
    3.9
    (2.8–5.5)
     Other1.8
    (1.4–2.3)
    2.0
    (1.3–3.0)
    1.8
    (1.4–2.2)
    2.7
    (1.8–4.2)
    1.9
    (1.0–3.8)
    3.9
    (2.3–6.3)
    3.5
    (2.4–4.8)
    3.2
    (2.1–4.9)
    3.7
    (2.4–5.8)
    Insurance, %
     Any private70.7
    (67.6–72.0)
    69.9
    (67.4–72.3)b
    70.9
    (69.5–72.3)b
    55.1
    (51.3–58.9)
    59.7
    (55.0–64.1)b
    48.8
    (43.5–54.1)b
    60.6
    (57.8–63.3)
    62.2
    (58.4–65.9)b
    58.8
    (54.9–62.6)b
     Public15.6
    (14.7–16.6)
    25.7
    (23.6–27.9)
    13.3
    (12.4–14.3)
    37.3
    (34.0–40.8)
    35.8
    (31.7–40.1)
    39.4
    (34.9–44.2)
    30.5
    (27.9–33.3)
    32.5
    (29.2–36.0)
    28.4
    (24.7–32.4)
     None13.7
    (12.8–14.6)
    4.4
    (3.6–5.5)
    15.8
    (14.8–16.9)
    7.6
    (6.1–9.3)
    4.5
    (3.1–6.7)
    11.8
    (9.1–15.1)
    8.9
    (7.5–10.6)
    5.3
    (3.6–7.7)
    12.8
    (10.7–15.3)
    • Note: Values are mean (95% CI) or percentage (95% CI).

    • ↵a Difference between those on a statin and not on a statin was significant (P <.05) with the adjusted Wald test.

    • ↵b Difference between those on a statin and not on a statin was significant (P <.05) with the χ2 test.

    • View popup
    Table 2

    Odds Ratios for Statin Use by Hyperlipidemia Status

    CharacteristicWith Hyperlipidemia Odds Ratio (95% CI)P ValueWithout Hyperlipidemia Odds Ratio (95% CI)P Value
    Coronary artery disease1.94 (1.58–2.40)<.00111.10 (5.51–22.80)<.001
    Diabetes1.90 (1.59–2.28)<.0018.56 (4.35–16.87)<.001
    Hypertension1.35 (1.14–1.60).0012.30 (1.29–4.11).005
    Cerebrovascular disease0.87 (0.64–1.17).360.59 (0.17–2.01).40
    Peripheral arterial disease1.04 (0.60–1.81).888.38 (2.71–25.93)<.001
    Tobacco use0.98 (0.82–1.16).761.26 (0.60–2.65).53
    Sex (male)1.19 (1.04–1.37).011.47 (0.81–2.66).21
    Age (per year)1.05 (1.04–1.05)<.0011.06 (1.03–1.09)<.001
    • Notes: An odds ratio exceeding 1 indicates higher likelihood of statin use. Odds ratios are adjusted for insurance status, race, and poverty category.

    • View popup
    Table 3

    Odds Ratios for Statin Use in Individuals Without Coronary Artery Disease or Diabetes

    CharacteristicOdds Ratio (95% CI)P Value
    Hyperlipidemia91.65 (60.27–139.36)<.001
    Age (per year)1.06 (1.05–1.07)<.001
    Hypertension1.35 (1.12–1.64).001
    Sex (male)1.33 (1.12–1.59).002
    Cerebrovascular disease1.52 (1.01–2.29).047
    Peripheral arterial disease1.59 (0.61–4.16).34
    Tobacco use1.00 (0.79–1.27).99
    • Notes: An odds ratio exceeding 1 indicates higher likelihood of statin use. Odds ratios are adjusted for insurance status, race, and poverty category.

Additional Files

  • Figures
  • Tables
  • The Article in Brief

    Cardiovascular Risk and Statin Use in the United States: A Cross-Sectional Analysis

    Michael E. Johansen , and colleagues

    Background New guidelines from the American College of Cardiology and American Heart Association substantially broaden the number of individuals for whom statin medications are recommended, primarily by expanding the eligible population to lower levels of cardiovascular risk. This study examines the relationships between statin use and cardiovascular risk, diagnosis of hyperlipidemia (high cholesterol and triglyceride levels), and other risk factors.

    What This Study Found Many people at high risk for cardiovascular disease, including those with coronary artery disease, diabetes or both, are not receiving statins. An estimated nine million people over 40 years of age with diabetes and 5.6 million people with coronary artery disease--populations that have clearly been shown to benefit from the drugs--are not on statins. Those with high cholesterol but without diabetes or heart disease are more likely to be on statins than those without high cholesterol but who have diabetes or heart disease. Given that individuals with heart disease or diabetes are at considerably higher cardiovascular risk, this pattern strongly supports the notion that statin use is being driven by high cholesterol instead of by overall cardiovascular risk.

    Implications

    • Recently released ACC-AHA guidelines offer an opportunity to reframe statins as medications that reduce cardiovascular risk rather than as medications that lower cholesterol.
  • Annals Journal Club

    May/Jun: Diagnosis or Risk Factors to Guide Statin Use?


    The Annals of Family Medicine encourages readers to develop a learning community of those seeking to improve health care and health through enhanced primary care. You can participate by conducting a RADICAL journal club and sharing the results of your discussions in the Annals online discussion for the featured articles. RADICAL is an acronym for Read, Ask, Discuss, Inquire, Collaborate, Act, and Learn. The word radical also indicates the need to engage diverse participants in thinking critically about important issues affecting primary care and then acting on those discussions.1

    HOW IT WORKS

    In each issue, the Annals selects an article or articles and provides discussion tips and questions. We encourage you to take a RADICAL approach to these materials and to post a summary of your conversation in our online discussion. (Open the article online and click on "TRACK Comments: Submit a response.") You can find discussion questions and more information online at: http://www.AnnFamMed.org/site/AJC/.

    CURRENT SELECTION

    Article for Discussion

    • Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular risk and statin use in the United States. Ann Fam Med. 2014;12(3):215-223.

    Discussion Tips

    This study provides a chance to consider factors associated with taking statin drugs in a nationally-representative sample of patients, and to consider the implications for our own prescribing practices.

    Discussion Questions

    • What question is asked by this study and why does it matter?
    • How does this study advance beyond previous research and clinical practice on this topic?
    • How strong is the study design for answering the question?
    • To what degree can the findings be accounted for by:
      1. How patients were selected, excluded, or lost to follow-up? (How representative is this nationally-representative survey?)
      2. How the main variables were measured?
      3. Confounding (false attribution of causality because 2 variables discovered to be associated actually are associated with a 3rd factor)?
      4. Chance?
      5. How the findings were interpreted?
    • What are the main study findings?
    • How comparable is the study sample to similar patients in your practice? What is your judgment about the transportability of the findings?
    • What contextual factors are important for interpreting the findings?2-5
    • How might this study change your practice? Policy? Education? Research?
    • Who the constituencies are for the findings, and how they might be engaged in interpreting or using the findings?
    • What are the next steps in interpreting or applying the findings?
    • What researchable questions remain?

    References

    1. Stange KC, Miller WL, McLellan LA, et al. Annals Journal Club: It's time to get RADICAL. Ann Fam Med. 2006;4(3):196-197.
    2. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;pii:S0735-1097(13)06028-2 (e-pub ahead of print).
    3. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;pii:S0735-1097(13)06029-4 (e-pub ahead of print);.
    4. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;pii:S0735-1097(13)06031-2 (e-pub ahead of print).
    5. Wenger NK. Prevention of Cardiovascular Disease: Highlights for the Clinician of the 2013 American College of Cardiology/American Heart Association Guidelines. Clin Cardiol. 2014;37(4):239-51.

PreviousNext
Back to top

In this issue

The Annals of Family Medicine: 12 (3)
The Annals of Family Medicine: 12 (3)
Vol. 12, Issue 3
May/June 2014
  • Table of Contents
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
  • In Brief
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Annals of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cardiovascular Risk and Statin Use in the United States
(Your Name) has sent you a message from Annals of Family Medicine
(Your Name) thought you would like to see the Annals of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Cardiovascular Risk and Statin Use in the United States
Michael Edward Johansen, Lee A. Green, Ananda Sen, Sheetal Kircher, Caroline R. Richardson
The Annals of Family Medicine May 2014, 12 (3) 215-223; DOI: 10.1370/afm.1641

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Get Permissions
Share
Cardiovascular Risk and Statin Use in the United States
Michael Edward Johansen, Lee A. Green, Ananda Sen, Sheetal Kircher, Caroline R. Richardson
The Annals of Family Medicine May 2014, 12 (3) 215-223; DOI: 10.1370/afm.1641
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Medications associated with fracture risk in patients with rheumatoid arthritis
  • Strategies for enhancing the initiation of cholesterol lowering medication among patients at high cardiovascular disease risk: a qualitative descriptive exploration of patient and general practitioners perspectives on a facilitated relay intervention in Alberta, Canada
  • Diagnosis of osteoporosis in statin-treated patients is dose-dependent
  • Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal
  • Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease
  • 2013 ACC/AHA Cholesterol Guideline Versus 2004 NCEP ATP III Guideline in the Prediction of Coronary Artery Calcification Progression in a Korean Population
  • Evidence-Based Policy Making: Assessment of the American Heart Associations Strategic Policy Portfolio: A Policy Statement From the American Heart Association
  • In This Issue: Many Arrows Rather than Magic Bullets
  • Do Clinical Guidelines Still Make Sense? Yes
  • Google Scholar

More in this TOC Section

  • Teamwork Among Primary Care Staff to Achieve Regular Follow-Up of Chronic Patients
  • Shared Decision Making Among Racially and/or Ethnically Diverse Populations in Primary Care: A Scoping Review of Barriers and Facilitators
  • Convenience or Continuity: When Are Patients Willing to Wait to See Their Own Doctor?
Show more Original Research

Similar Articles

Subjects

  • Domains of illness & health:
    • Chronic illness
    • Prevention
  • Methods:
    • Quantitative methods
  • Other research types:
    • Health policy
    • Health services

Keywords

  • cardiovascular: coronary artery disease
  • cardiovascular: hyperlipidemia
  • endocrinology: diabetes
  • primary care issues

Content

  • Current Issue
  • Past Issues
  • Early Access
  • Plain-Language Summaries
  • Multimedia
  • Podcast
  • Articles by Type
  • Articles by Subject
  • Supplements
  • Calls for Papers

Info for

  • Authors
  • Reviewers
  • Job Seekers
  • Media

Engage

  • E-mail Alerts
  • e-Letters (Comments)
  • RSS
  • Journal Club
  • Submit a Manuscript
  • Subscribe
  • Family Medicine Careers

About

  • About Us
  • Editorial Board & Staff
  • Sponsoring Organizations
  • Copyrights & Permissions
  • Contact Us
  • eLetter/Comments Policy

© 2025 Annals of Family Medicine